Funding: This study was funded by the National Institute for Health Research (NIHR) Research for Patient Benefit programme (PB-PG-0110-21244), Department of Health, UK. The funder was not involved in the study design. Acknowledgments: The authors gratefully acknowledge support from the Cancer Research UK Clinical Trials Unit, the UK Dermatology Clinical Trials Network, the NIHR Clinical Studies Group, and support for investigators from the British Skin Foundation and Cancer Research UK. We would also like to thank Martin Jones, Daniel Rigby and Ariel Bergmann for constructive comments on the design of the DCE.Peer reviewedPostprin
Contains fulltext : 168092.pdf (publisher's version ) (Open Access)Actinic keratos...
Introduction:Treatment adherence continues to be a major challenge in psoriasis. Patient preference ...
Background: Decreased illness perception among actinic keratoses (AK) patients is a major barrier to...
Background: The treatment of actinic keratosis (AK) is a potentially effective strategy for the prev...
Background: The treatment of actinic keratosis (AK) is a potentially effective strategy for the pr...
AbstractBackgroundTopical therapy is important in the treatment of actinic keratosis (AK), a major r...
Acknowledgements: Catherine Harwood, PhD as chief investigator and Charlotte Proby, MA, John Lear, M...
Background: The SINS trial (Controlled Clinical Trials ISRCTN48755084; Eudract No. 2004-004506-24) i...
BACKGROUND: A wide variety of both surgical and nonsurgical therapies is currently available for pat...
Question What are the most important outcomes to report in clinical trials on actinic keratosis? Fin...
BACKGROUND: A wide variety of both surgical and nonsurgical therapies is currently available for...
Background Follow-up after low-risk basal cell carcinoma (BCC) is being provided more frequently th...
Introduction:Treatment adherence continues to be a major challenge in psoriasis. Patient preference ...
Actinic keratosis (AK) is a common skin disease related to ultraviolet chronic exposure, that is now...
Background Follow-up after low-risk basal cell carcinoma (BCC) is being provided more frequently tha...
Contains fulltext : 168092.pdf (publisher's version ) (Open Access)Actinic keratos...
Introduction:Treatment adherence continues to be a major challenge in psoriasis. Patient preference ...
Background: Decreased illness perception among actinic keratoses (AK) patients is a major barrier to...
Background: The treatment of actinic keratosis (AK) is a potentially effective strategy for the prev...
Background: The treatment of actinic keratosis (AK) is a potentially effective strategy for the pr...
AbstractBackgroundTopical therapy is important in the treatment of actinic keratosis (AK), a major r...
Acknowledgements: Catherine Harwood, PhD as chief investigator and Charlotte Proby, MA, John Lear, M...
Background: The SINS trial (Controlled Clinical Trials ISRCTN48755084; Eudract No. 2004-004506-24) i...
BACKGROUND: A wide variety of both surgical and nonsurgical therapies is currently available for pat...
Question What are the most important outcomes to report in clinical trials on actinic keratosis? Fin...
BACKGROUND: A wide variety of both surgical and nonsurgical therapies is currently available for...
Background Follow-up after low-risk basal cell carcinoma (BCC) is being provided more frequently th...
Introduction:Treatment adherence continues to be a major challenge in psoriasis. Patient preference ...
Actinic keratosis (AK) is a common skin disease related to ultraviolet chronic exposure, that is now...
Background Follow-up after low-risk basal cell carcinoma (BCC) is being provided more frequently tha...
Contains fulltext : 168092.pdf (publisher's version ) (Open Access)Actinic keratos...
Introduction:Treatment adherence continues to be a major challenge in psoriasis. Patient preference ...
Background: Decreased illness perception among actinic keratoses (AK) patients is a major barrier to...